Publicaciones en colaboración con investigadores/as de Hospital Universitari de Girona Dr. Josep Trueta (29)

2023

  1. Safety and Efficacy of ApTOLL in Patients with Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial

    JAMA Neurology, Vol. 80, Núm. 8, pp. 779-788

2014

  1. Characterization of Gcf2/Lrrfip1 in experimental cerebral ischemia and its role as a modulator of Akt, mTOR and β-catenin signaling pathways

    Neuroscience, Vol. 268, pp. 48-65

  2. Oct-2 transcription factor binding activity and expression up-regulation in rat cerebral ischaemia is associated with a diminution of neuronal damage in vitro

    NeuroMolecular Medicine, Vol. 16, Núm. 2, pp. 332-349

  3. The high-mobility group I-Y transcription factor is involved in cerebral ischemia and modulates the expression of angiogenic proteins

    Neuroscience, Vol. 269, pp. 112-130

2013

  1. MiRNA expression is modulated over time after focal ischaemia: Up-regulation of miR-347 promotes neuronal apoptosis

    FEBS Journal, Vol. 280, Núm. 23, pp. 6233-6246

2011

  1. A mouse model of hemorrhagic transformation by delayed tissue plasminogen activator administration after in situ thromboembolic stroke

    Stroke, Vol. 42, Núm. 1, pp. 196-203

  2. Tests neurológicos para la evaluación del pronóstico funcional en modelos de ictus isquémico en roedores

    Revista de Neurologia, Vol. 53, Núm. 10, pp. 607-618

2009

  1. Synthesis of lipoxin A 4 by 5-lipoxygenase mediates pparγ-dependent, neuroprotective effects of rosiglitazone in experimental stroke

    Journal of Neuroscience, Vol. 29, Núm. 12, pp. 3875-3884

  2. Validation of housekeeping genes for quantitative real-time PCR in in-vivo and in-vitro models of cerebral ischaemia

    BMC Molecular Biology, Vol. 10

2007

  1. Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARγ target gene involved in neuroprotection

    Journal of Cerebral Blood Flow and Metabolism, Vol. 27, Núm. 7, pp. 1327-1338

  2. Statin treatment withdrawal in ischemic stroke: A controlled randomized study

    Neurology, Vol. 69, Núm. 9, pp. 904-910

  3. The increase of circulating endothelial progenitor cells after acute ischemic stroke is associated with good outcome

    Stroke, Vol. 38, Núm. 10, pp. 2759-2764

2006

  1. A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke

    Journal of Experimental Medicine, Vol. 203, Núm. 3, pp. 711-717

  2. High blood pressure and inflammation are associated with poor prognosis in lacunar infarctions

    Cerebrovascular Diseases, Vol. 22, Núm. 2-3, pp. 123-129

  3. Hyperthermia is a surrogate marker of inflammationmediated cause of brain damage in acute ischaemic stroke

    Journal of Internal Medicine, Vol. 260, Núm. 4, pp. 343-349

  4. Micro- and macroalbuminuria predict hemorrhagic transformation in acute ischemic stroke

    Neurology, Vol. 67, Núm. 7, pp. 1172-1177

  5. New-onset hypertension and inflammatory response/poor outcome in acute ischemic stroke

    Neurology, Vol. 67, Núm. 11, pp. 1973-1978

  6. Rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J 2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms

    Journal of Cerebral Blood Flow and Metabolism, Vol. 26, Núm. 2, pp. 218-229

  7. Targets of cytoprotection in acute ischemic stroke: Present and future

    Cerebrovascular Diseases, Vol. 21, Núm. SUPPL. 2, pp. 1-8

2005

  1. Increased plasma levels of 15-deoxy Δ prostaglandin J2 are associated with good outcome in acute atherothrombotic ischemic stroke

    Stroke, Vol. 36, Núm. 6, pp. 1189-1194